Skip to content. | Skip to navigation

Navigation

Personal tools
You are here: ROADS at McMaster > Events > The Michael J. Fox Foundation: Targeted Funding Opportunities

The Michael J. Fox Foundation: Targeted Funding Opportunities

When May 10, 2018
from 12:00 PM to 01:00 PM
Where Webinar
Add event to calendar vCal
iCal

 

 

 

 

 

Webinar 
May 10, 2018 at 12:00pm-1:00pm

Register: https://www.michaeljfox.org/understanding-parkinsons/webinar-registration.php?id=38&e=1635395&k=1AD2D63CFE01AA61356D571F609020CC



The Michael J. Fox Foundation (MJFF) has recently announced the following funding programs:

1)  Alpha-synuclein Biology and Therapies, the objective: to support projects aimed at altering intracellular alpha-synuclein in order to broaden the scope of therapeutic approaches.

focus:
. the role of alpha-synuclein and modified forms in health and disease;
. the relationship between alpha-synuclein structure and physiological functions;
. novel therapeutic approaches targeting intracellular alpha-synuclein, or related pathways.
Value:
Biological Pathways & Novel Targets: maximum $150,000

Therapeutic Development: maximum $500,000
1-2 year grants
https://www.michaeljfox.org/research/grant-detail.php?id=34


2)  Biomarkers of Protein Handling/Autophagy, Exosomes and Lipids, the objective: to advance biomarker assays in three highly relevant Parkinson's disease (PD) biology research areas:

. protein handling/autophagy pathways
. exosomes of neuronal origin (including assays to measure proteins, nucleic acids, lipids or metabolites)
. lipids (including absolute and relative quantification and identification of lipid series)
Value:
commensurable with the study goals
1-2 year grants
https://www.michaeljfox.org/research/grant-detail.php?id=36


3)  GBA Biology and Therapies, the objective: to advance the understanding of glucocerebrosidase (GBA) biology and accelerate therapeutic approaches.

focus:
. How GBA mutations lead to PD
. Mechanisms underlying GCase dysfunction in the absence of GBA mutations
. Novel therapeutic interventions to prevent pathogenic mechanisms triggered by GCase-pathway dysfunction
Value:
Biological Pathways & Novel Targets: maximum $150,000

Therapeutic Development: maximum $500,000
1-2 year grants
https://www.michaeljfox.org/research/grant-detail.php?id=35


4)  Non-Pharmacological Interventions for Gait and Balance Disturbances, the objective:  to test non-pharmacological interventions for the treatment of gait and balance disturbances in people with PD

focus:
. assistive devices (e.g., back or leg braces);
. novel technologies (e.g., laser or wearable devices) (novel technologies must have at least a prototype available to test for proof of concept);
. rehabilitative therapy programs (e.g., occupational or physical therapy).

Projects may aim to analyze preliminary existing data around devices or programs. At the end of the proposed project period, the technology or approach must have the potential to be quickly integrated into patient care.
Value:
maximum $500,000
1-2 year grants
https://www.michaeljfox.org/research/grant-detail.php?id=37

https://www.michaeljfox.org/research/apply-for-grant.html

Application process:
The MJFF pre-proposal deadline is May 31, 2018

ROADS contact:
Virginia Viscardi, Senior Advisor, at viscarvl@mcmaster.ca or extension 24519